Afferent Pharmaceuticals Raises $55 Million in Oversubscribed Crossover Financing
July 8, 2015Afferent Pharmaceuticals completes a $55 million Series C financing to fund the advancement of the first-in-class drug candidate, AF-219, for the treatment of pathologic cough. The Phase 2b study of AF-219 recently completed enrollment and top-line data i
More »
Esperion Therapeutics Announces Removal of 240 mg Partial Clinical Hold for ETC-1002
July 7, 2015Esperion Therapeutics announced the FDA has removed the 240 mg partial clinical hold on ETC-1002, which means it can be used at doses above 240 mg in clinical studies. Esperion plans to initiate the Phase 3 clinical program in Q4 of this year using the al
More »
Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF)
July 6, 2015Celtaxsys gains FDA clearance to begin a U.S. Phase 2 clinical trial of its flagship drug candidate, CTX-4430, in adult patients with cystic fibrosis. This study was designed in consultation with Cystic Fibrosis Foundation Therapeutics, Inc.
More »